Literature DB >> 15231656

DNA hypomethylation and ovarian cancer biology.

Martin Widschwendter1, Guanchao Jiang, Christian Woods, Hannes M Müller, Heidi Fiegl, Georg Goebel, Christian Marth, Elisabeth Müller-Holzner, Alain G Zeimet, Peter W Laird, Melanie Ehrlich.   

Abstract

Hypomethylation of some portions of the genome and hypermethylation of others are very frequent in human cancer. The hypomethylation often involves satellite 2 (Sat2) DNA in the juxtacentromeric (centromere-adjacent) region of chromosome 1. In this study, we analyzed methylation in centromeric and juxtacentromeric satellite DNA in 115 ovarian cancers, 26 non-neoplastic ovarian specimens, and various normal somatic tissue standards. We found that hypomethylation of both types of satellite DNA in ovarian samples increased significantly from non-neoplastic toward cancer tissue. Furthermore, strong hypomethylation was significantly more prevalent in tumors of advanced stage or high grade. Importantly, extensive hypomethylation of Sat2 DNA in chromosome 1 was a highly significant marker of poor prognosis (relative risk for relapse, 4.1, and death, 9.4) and more informative than tumor grade or stage. Also, comparing methylation of satellite DNA and 15 5' gene regions, which are often hypermethylated in cancer or implicated in ovarian carcinogenesis, we generally found no positive or negative association between methylation changes in satellite DNA and in the gene regions. However, hypermethylation at two loci, CDH13 (at 16q24) and RNR1 (at 13p12), was correlated strongly with lower levels of Sat2 hypomethylation. The CDH13/Sat2 epigenetic correlation was seen also in breast cancers. We conclude that satellite DNA hypomethylation is an important issue in ovarian carcinogenesis as demonstrated by: (a) an increase from non-neoplastic tissue toward ovarian cancer; (b) an increase within the ovarian cancer group toward advanced grade and stage; and (c) the finding that strong hypomethylation was an independent marker of poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231656     DOI: 10.1158/0008-5472.CAN-04-0238

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  77 in total

1.  N6-methyladenine DNA Modification in Glioblastoma.

Authors:  Qi Xie; Tao P Wu; Ryan C Gimple; Zheng Li; Briana C Prager; Qiulian Wu; Yang Yu; Pengcheng Wang; Yinsheng Wang; David U Gorkin; Cheng Zhang; Alexis V Dowiak; Kaixuan Lin; Chun Zeng; Yinghui Sui; Leo J Y Kim; Tyler E Miller; Li Jiang; Christine H Lee; Zhi Huang; Xiaoguang Fang; Kui Zhai; Stephen C Mack; Maike Sander; Shideng Bao; Amber E Kerstetter-Fogle; Andrew E Sloan; Andrew Z Xiao; Jeremy N Rich
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

Review 2.  Epigenetics and human disease: translating basic biology into clinical applications.

Authors:  David Rodenhiser; Mellissa Mann
Journal:  CMAJ       Date:  2006-01-31       Impact factor: 8.262

Review 3.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

Review 4.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

5.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

7.  Small molecules capable of activating DNA methylation-repressed genes targeted by the p38 mitogen-activated protein kinase pathway.

Authors:  Xiang Li; Erchang Shang; Qiang Dong; Yingfeng Li; Jing Zhang; Shaohua Xu; Zuodong Zhao; Wei Shao; Cong Lv; Yong Zheng; Hailin Wang; Xiaoguang Lei; Bing Zhu; Zhuqiang Zhang
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

8.  Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.

Authors:  M Ehrlich; C B Woods; M C Yu; L Dubeau; F Yang; M Campan; D J Weisenberger; Ti Long; B Youn; E S Fiala; P W Laird
Journal:  Oncogene       Date:  2006-04-27       Impact factor: 9.867

Review 9.  Breast cancer epigenetics: from DNA methylation to microRNAs.

Authors:  Jürgen Veeck; Manel Esteller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

10.  DNA methylation-mediated down-regulation of DNA methyltransferase-1 (DNMT1) is coincident with, but not essential for, global hypomethylation in human placenta.

Authors:  Boris Novakovic; Nick C Wong; Mandy Sibson; Hong-Kiat Ng; Ruth Morley; Ursula Manuelpillai; Thomas Down; Vardhman K Rakyan; Stephan Beck; Stefan Hiendleder; Claire T Roberts; Jeffrey M Craig; Richard Saffery
Journal:  J Biol Chem       Date:  2010-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.